Abstract
* Elotuzumab (Empliciti) is a new monoclonal antibody approved to treat multiple myeloma in combination with lenalidomide (Revlimid) and dexamethasone.
* Use is restricted to patients who have already received one to three drug therapies to treat the condition.
* Elotuzumab commonly produces infusion reactions, and premedication is necessary. Patients may also develop second primary malignancies or hepatotoxicity. Response to the drug can be difficult to measure.